FIELD: pharmaceuticals.
SUBSTANCE: invention relates to the field of pharmacology, in particular, to pharmaceutical compositions for preventing and treating polycystic ovary syndrome (PCOS), containing the following components, % wt.: vitamin D3 - from 0.0006 to 0.001; vitamin B9 (folic acid) - from 0.004 to 0.006; alpha lipoic acid - from 5.3 to 7.1; myo inositol - from 89.9 to 92.5; D-chiro-inositol - from 2.0 to 2.6; manganese gluconate - from 0.35 to 0.47.
EFFECT: production of pharmaceutical compositions for preventing and treating polycystic ovary syndrome (PCOS) with increased efficiency of use and with an increased duration of effect (bodily system normalisation period).
1 cl, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATMENT OF POLYCYSTIC OVARY SYNDROME ASSOCIATED WITH METABOLIC SYNDROME | 2020 |
|
RU2749783C1 |
| METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS OF METFORMIN AND/OR WEIGHT-LOSS THERAPY IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME | 2010 |
|
RU2427842C1 |
| METHOD FOR TREATING CHRONIC ANOVULATION AND PREVENTING SYNDROME OF OVARIAN HYPERSTIMULATION | 1999 |
|
RU2201225C2 |
| TREATMENT OF HEPATIC STEATOSIS RELATED OLIGO-OVULATION | 2016 |
|
RU2745606C2 |
| METHOD FOR TREATMENT OF POLYCYSTIC OVARIAN SYNDROME BASED ON EXPERIMENTAL MODEL OF WISTAR RATS | 2021 |
|
RU2776131C1 |
| METHOD OF CORRECTING MENSTRUAL IRREGULARITIES IN WOMEN WITH METABOLIC SYNDROME | 2022 |
|
RU2813333C1 |
| METHOD OF DERMATOSIS DEVELOPMENT PREDICTION IN WOMEN WITH SCLEROPOLYCYSTIC OVARIAN SYNDROME (SPCO) | 2008 |
|
RU2367954C1 |
| METHOD OF DIAGNOSTIC ANOVULATION | 2016 |
|
RU2650627C1 |
| METHOD FOR TREATING OVARY POLYCYSTOSIS WITH LASER RADIATION | 2000 |
|
RU2169024C1 |
| METHOD FOR MODELING POLYCYSTIC OVARIES AT PREDOMINANCE OF FOLLICULAR CYSTS | 2005 |
|
RU2282249C1 |
